153.70USD+1.41%Mkt Cap: 32.84B USDP/E: —Last update: 2026-05-26
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that bind…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
31.18BSEKP/E 46.1
31.10BUSDP/E 28.4
Indicators:|
Key Statistics
Company
Market Cap32.84B USD
Enterprise Value31.21B USD
Revenue (TTM)—
Gross Profit-1.13B USD
Net Income (TTM)-1.13B USD
Revenue/Share—
Last Price153.70 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees883
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-27.17
PEG—
EV/EBITDA-22.64
EV/Revenue—
P/S—
P/B20.52
EPS (TTM)-7.11
EPS (Forward)-5.66
52W Range
34.0098% of range156.24
52W High156.24 USD
52W Low34.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.35%
ROA-48.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-897.74M USD
CapEx (TTM)15.99M USD
FCF Margin—
FCF Yield-1.85%
Net Debt-1.47B USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.10
Current Ratio6.79
Quick Ratio6.59
Book Value/Sh7.493 USD
Cash/Share8.975 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)184.45 USD
Target Range165.00 USD – 263.00 USD
# Analysts20
Ownership
Shares Out.212.60M
Float194.18M
Insiders1.90%
Institutions95.50%
Short Interest
Short Ratio3.1d
Short % Float6.36%
Short % Out.6.02%
Shares Short12.80M
Short (prev mo.)15.41M
Technical
SMA 50124.48 (+23.5%)
SMA 20084.00 (+83.0%)
Beta1.41
S&P 52W Chg28.31%
Avg Vol (30d)3.39M
Avg Vol (10d)2.03M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—